Don't Jump to Saxenda for Weight Loss in Adolescents

Saxenda (liraglutide) will be a new option to help tackle obesity in adolescents 12 and up...not just in adults.

About 30% of Canadian kids aged 5 to 17 are overweight or obese. This may lead to adulthood obesity and a higher risk of chronic problems...type 2 diabetes, heart disease, sleep apnea, etc.

Explain that 1 year of the GLP-1 agonist Saxenda in adolescents leads to about a 5% decrease in BMI or body weight compared to placebo...or about 5 kg for a 100 kg patient.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote